^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    Folate receptor 1-targeted antibody-drug conjugate

    Related drugs:
    2d
    RAINFOL-09: Study to Assess the Efficacy and Safety of Rina-S in Participants With Advanced Gastrointestinal (GI) Cancers (clinicaltrials.gov)
    P2, N=160, Not yet recruiting, Genmab
    New P2 trial
    |
    Rina-S (rinatabart sesutecan)
    3d
    RAINFOL-05: Study to Assess the Efficacy and Safety of Rina-S in Participants With Non-small Cell Lung Cancer (clinicaltrials.gov)
    P2, N=62, Recruiting, Genmab
    New P2 trial
    |
    Rina-S (rinatabart sesutecan)
    3d
    GCT1184-03: Study to Assess the Efficacy and Safety of Rina-S Compared to Treatment of Investigators Choice in Participants With Endometrial Cancer ( RAINFOL-03 ) (2024-519818-31-01)
    P2/3, N=194, Not yet recruiting, Genmab A/S
    New P2/3 trial
    |
    paclitaxel • doxorubicin hydrochloride • Rina-S (rinatabart sesutecan)
    5d
    Safety and Antitumor Activity of Farletuzumab Ecteribulin in Patients With NSCLC: Phase I Expansion Results. (PubMed, JTO Clin Res Rep)
    FZEC demonstrated modest antitumor activity, and observed AEs were generally manageable in patients with heavily pretreated NSCLC. NCT03386942.
    P1 data • Journal
    |
    FOLR1 ( Folate receptor alpha )
    |
    FOLR1 expression
    |
    Halaven (eribulin mesylate) • farletuzumab ecteribulin (MORAb-202)
    7d
    GCT1184-05: Study to assess the efficacy and safety of Rina-S in participants with non-small cell lung cancer (2025-522107-18-00)
    P1/2, N=34, Not yet recruiting, Genmab A/S
    New P1/2 trial
    |
    Neulasta (pegfilgrastim) • Rina-S (rinatabart sesutecan)
    9d
    Corneal Toxicity of Mirvetuximab Soravtansine: Multimodal Imaging Features and Implications for Ophthalmologic Management. (PubMed, Diagnostics (Basel))
    MIRV-related ocular alterations are frequent but reversible and clinically manageable. Multimodal imaging combined with functional and refractive assessment provides sensitive markers of corneal epithelial toxicity and supports integrated ophthalmologic monitoring to preserve visual function and maintain oncologic treatment continuity.
    Journal
    |
    FOLR1 ( Folate receptor alpha )
    |
    Elahere (mirvetuximab soravtansine-gynx)
    9d
    An Evaluation of Maintenance Therapy Combination Mirvetuximab Soravtansine and Olaparib (clinicaltrials.gov)
    P2, N=53, Recruiting, University of Colorado, Denver | Trial completion date: Oct 2028 --> Jan 2031 | Trial primary completion date: Jan 2028 --> Jan 2029
    Trial completion date • Trial primary completion date • Platinum sensitive
    |
    BRCA (Breast cancer early onset)
    |
    BRCA mutation
    |
    Lynparza (olaparib) • Elahere (mirvetuximab soravtansine-gynx)
    14d
    Characterizing therapeutic target antigen expression in anaplastic carcinoma of the ovary. (PubMed, Gynecol Oncol Rep)
    FOLR1 expression in the two cases was weak and below currently used clinical cutoffs for mirvetuximab soravtansine eligibility...Only a subset of anaplastic carcinomas of the ovary express targetable tumor antigens at low levels, suggesting that these may have limited benefit from antibody-drug conjugates. Likewise, due to mismatch repair proficiency and low tumor mutational burden, immunotherapy is unlikely to be effective in this rare disease.
    Journal • Tumor mutational burden • IO biomarker
    |
    HER-2 (Human epidermal growth factor receptor 2) • TMB (Tumor Mutational Burden) • FOLR1 ( Folate receptor alpha ) • MLH1 (MutL homolog 1) • MSH6 (MutS homolog 6) • MSH2 (MutS Homolog 2) • PMS2 (PMS1 protein homolog 2) • TACSTD2 (Tumor Associated Calcium Signal Transducer 2)
    |
    HER-2 expression • TMB-L • FOLR1 expression
    |
    Elahere (mirvetuximab soravtansine-gynx)
    16d
    TSL-B2276-1-01: A Study of STRO-002 in Chinese Adults With Epithelial Ovarian Cancer and Other Advanced Malignant Solid Tumors (clinicaltrials.gov)
    P1/2, N=19, Completed, Tasly Pharmaceutical Group Co., Ltd | Recruiting --> Completed | N=132 --> 19 | Trial completion date: Dec 2027 --> Dec 2025 | Trial primary completion date: Dec 2026 --> Jun 2025
    Trial completion • Enrollment change • Trial completion date • Trial primary completion date
    |
    HER-2 (Human epidermal growth factor receptor 2) • PGR (Progesterone receptor)
    |
    HER-2 negative
    |
    luveltamab tazevibulin (STRO-002)
    21d
    TREVI-OC-01: AZD5335 vs. Mirvetuximab Soravtansine in FRα-high and AZD5335 vs. Chemotherapy in FRα-low Platinum-resistant Ovarian Cancer (clinicaltrials.gov)
    P3, N=289, Recruiting, AstraZeneca | N=46 --> 289
    Enrollment change • Platinum resistant
    |
    BRCA (Breast cancer early onset)
    |
    BRCA mutation
    |
    paclitaxel • pegylated liposomal doxorubicin • Elahere (mirvetuximab soravtansine-gynx) • topotecan • torvutatug samrotecan (AZD5335)
    21d
    GCT1184-03: Study to Assess the Efficacy and Safety of Rina-S Compared to Treatment of Investigators Choice in Participants With Endometrial Cancer ( RAINFOL-03 ) (2024-519818-31-01)
    P2/3, N=98, Not yet recruiting, Genmab A/S
    New P2/3 trial
    |
    paclitaxel • doxorubicin hydrochloride • Rina-S (rinatabart sesutecan)
    24d
    GCT1184-03: Study to Assess the Efficacy and Safety of Rina-S Compared to Treatment of Investigators Choice in Participants With Endometrial Cancer ( RAINFOL-03 ) (2024-519818-31-01)
    P2/3, N=51, Not yet recruiting, Genmab A/S
    New P2/3 trial
    |
    paclitaxel • doxorubicin hydrochloride • Rina-S (rinatabart sesutecan)